Introduction {#s1}
============

The ability to precisely edit genomes holds great promise for a wide range of applications in both biomedical research and the treatment of human genetic diseases ([@bib44]; [@bib45]). In recent years, a number of genome editing tools including zinc-finger nucleases ([@bib4]; [@bib29]; [@bib32]), transcription activator-like effector nucleases (TALENs) ([@bib48]) and the RNA-guided CRISPR/Cas9 nuclease system ([@bib23]) have been developed. Among them, the adapted *Streptococcus pyogenes* CRISPR/Cas9 (SpCRISPR/Cas9) has received the greatest attention due to its simplicity, relative high precision and flexibility ([@bib15]). The SpCRISPR/Cas9-mediated genome editing system consists of the Cas9 nuclease protein and a single guide RNA (sgRNA) containing a 20-nucleotide (nt) sequence with complementary pairing to a target genomic locus adjacent to a 5'NGG3' protospacer adjacent motif (PAM). When combined with an sgRNA, the Cas9 nuclease generates a DNA double-strand break (DSB) around 3 bp upstream the target PAM sequence ([@bib9]; [@bib23]).

Upon DSB induction, two different DSB repair mechanisms are available to repair the lesion -- homologous recombination (HR) and non-homologous end joining (NHEJ). The choice of DSB repair pathway determines the outcome of the genome editing. In the presence of a homologous template, successful HR results in a precise knock-in event ([@bib34]). By contrast, the error-prone NHEJ probably leads to a phenotype of gene knock-out ([@bib53]). Many factors, including cell cycle stage ([@bib50]), competition between DNA damage repair factors such as RIF1/53BP1 vs. BRCA1/CtIP ([@bib13]; [@bib43]) and cell type collectively influence the choice between HR and NHEJ. Great efforts have been made to improve the efficiency of SpCRISPR/Cas9-mediated knock-in ([@bib41]). Knocking down the DNA damage response factor, 53BP1, which favors the choice of NHEJ ([@bib5]); or important NHEJ factors such as KU70, KU80 and LIG4 ([@bib8]) promotes the SpCRISPR/Cas9-mediated knock-in efficiency ([@bib52]). In addition, a number of small molecules inhibiting NHEJ or promoting HR have been shown to improve knock-in efficiency ([@bib36]). For instance, suppressing NHEJ by blocking LIG4 activity with SCR7, or inhibiting DNA-PKcs kinase activity with NU7441 or NU7026, has been shown to improve the precise targeting efficiency of SpCRISPR/Cas9 ([@bib8]; [@bib37]; [@bib55]). Similarly, stimulating the HR factor, RAD51, with RS-1 also improved SpCRISPR/Cas9 editing efficiency ([@bib14]). However, both inhibiting NHEJ and stimulating the activity of the recombinase involved in HR are potentially harmful to the maintenance of genome integrity ([@bib6]; [@bib46]). NHEJ is the major pathway for mending the broken ends in mammalian cells in all cell cycle stages ([@bib24]). Loss of this pathway often leads to high cancer incidences and premature aging ([@bib21]; [@bib47]). The risk of activating RAD51 is that it might increase the chance of the spontaneous recombination with prevalent repetitive sequences in mammalian cells, resulting in the loss of large amounts of genetic information ([@bib17]; [@bib35]). Therefore, there is a need to expand the list of the compounds which can improve the efficiency of precise genome editing with minimal or no effect on global genome stability.

Here, based on our recently developed cell lines containing a dual-reporter for the simultaneous measurement of both HR and NHEJ efficiency at the same chromosomal site ([@bib7]), we generated a novel, rapid, quantitative and easy-to-score screening platform for identifying compounds that could be potentially applied in SpCRISPR/Cas9-mediated genome editing. Using the system, we screened 722 small molecules isolated from herbs used in traditional Chinese medicine. We found that farrerol, a natural compound isolated from *Rhododendron dauricum*, which exhibits antibechic, anti-bacterial and anti-inflammatory properties ([@bib54]), promoted HR but had no effect on NHEJ. Further mechanistic studies indicated that farrerol stimulated the recruitment of RAD51 to DSB sites rather than changed the expression levels of HR related factors. We then demonstrated that farrerol facilitated SpCRISPR/Cas9-mediated genome targeting at different loci in human somatic cells, mouse embryonic stem cells (ESCs) and mouse embryos. In contrast, SCR7 and RS-1, two most commonly used small molecules for gene targeting, exhibited a position dependent effect on targeting efficiency in different cell lines and also in mouse embryos. Moreover, we demonstrated that farrerol did not destabilize genomes using comet assay, karyotype analysis and immunofluorescence staining of genotoxic markers. Conversely, treating cells with SCR7, which blocks the NHEJ pathway, and RS-1, which activates RAD51, diminished genome integrity. Besides, we also found that farrerol could significantly suppress the efficiency of single strand annealing (SSA), which may cause deletions of large fragments between repetitive sequences in genomes ([@bib49]), while RS-1 had no effect on SSA efficiency. Moreover, treating mouse ESCs and blastocysts with farrerol had no adverse effect on cell growth and embryo development, whereas we observed abnormal development in mouse blastocysts treated with SCR7, and we failed to observe a remarkable stimulatory effect on knock-in efficiency in RS-1 treated mouse blastocysts. Most intriguingly, farrerol significantly improved the efficiency of SpCRISPR/Cas9-mediated knock-in in blastocysts, and the generated knock-in founder mice retained the capability for germline transmission.

Results {#s2}
=======

Generation of a high-throughput compound screening platform for monitoring the choice of DSB repair pathway {#s2-1}
-----------------------------------------------------------------------------------------------------------

To identify novel compounds that can potentially enhance precise genome editing efficiency, we created CLZ3, a cell line suitable for high-throughput drug screening. The cell line contains a reporter cassette for the simultaneous detection of both HR and NHEJ efficiency at the same locus upon DSB induction at the I-SceI recognition sites ([Figure 1A](#fig1){ref-type="fig"}), and a chromosomally integrated doxycycline-inducible vector encoding the endonuclease, I-SceI ([Figure 1B](#fig1){ref-type="fig"}). The CLZ3 cell line was derived from the previously described D4a human fibroblast cell line ([@bib7]), which was developed to measure the efficiency of both HR and NHEJ simultaneously at the same chromosomal site. In the dual HR-NHEJ reporter cassette ([Figure 1A](#fig1){ref-type="fig"}), the part downstream of the CMV promoter consists of two GFP exons, the engineered rat Pem1 intron separating the two GFP exons, an adenoviral exon (AD2) flanked by recognition sequences for I-SceI endonuclease in an inverted orientation and an ATG-less tdTomato gene. In the part upstream of the CMV promoter, the reporter cassette contains the Pem1 intron and the inserted full length tdTomato gene. The inducible vector for I-SceI expression is comprised of two parts in an inverted orientation to avoid potential interference from one another ([Figure 1B](#fig1){ref-type="fig"}). The first part contains the coding sequence of reverse tetracycline-controlled transactivator (rtTA) driven by a constitutively active CAG promoter (P~CAG~). The second part encodes the I-SceI-NLS (Nuclear localization sequence) -HA endonuclease driven by a TET response element (TRE) promoter.

![Establishment of a compound screening platform for monitoring the efficiency of DSB repair by HR and NHEJ.\
(**A**) Diagram of the HR-NHEJ dual fluorescent reporter ([@bib7]). SD, splice donor; SA, splice acceptor. In the reporter cassette for simultaneous analysis of HR and NHEJ at the same chromosomal site, it contains two parts separated by a CMV promoter. The part downstream of the promoter contains two GFP exons separated by the engineered Pem1 intron with splice donor and acceptor, an adenoviral exon (AD2) with splice donor and acceptor, two I-SceI recognition sites in an inverted orientation, and an ATG-less tdTomato gene. The second part upstream of the promoter contains the Pem1 intron and a full-length tdTomato gene with a splice donor before start codon ATG. The homology region between the two parts of the reporter is approximately 3.9 kb including the rat Pem1 intron (marked in yellow line) and the tdTomato gene. (**B**) Schematic diagram of the doxycycline-inducible I-SceI expression vector. rtTA, reverse tetracycline trans-activator protein; PTRE, promoter of tetracycline response element; PCAG, the CAG promoter, a strong synthetic promoter frequently used to drive high levels of gene expression in mammalian systems. (**C--D**) Generation of the compound screening platform. The linearized doxycycline-inducible I-SceI expression vector was nucleofected into D4a cells followed by selection with 30 μg/mL hygromycin B. Then individual colonies were picked and one of the colonies, CLZ3, was utilized for further studies. I-SceI endonuclease expression could be efficiently induced upon doxycycline supplementation (**C**), further resulting in the generation of DSBs on the reporter cassette. Successful repair by HR or NHEJ results in functional tdTomato or GFP, turning cells red or green respectively, which could be observed via microscopy (**D**). (**E**) Flow cytometry analysis of tdTomato^+^ and GFP^+^ cells upon doxycycline addition (left panel). The representative FACS traces are shown (right panel). (**F**) Workflow of compound screening using the CLZ3 cell line. (**G**) 722 small molecules were screened using CLZ3 cells and farrerol (highlighted in blue) was identified as an HR enhancer.\
Figure 1---source data 1.The list of small molecule compounds and their influences on DNA repair.\
Figure 1---source data 2.Summary of NHEJ, HR and SSA efficiency.](elife-56008-fig1){#fig1}

In brief, in the absence of doxycycline, the CLZ3 cells do not express the I-SceI endonuclease, thus no DSBs are generated, and cells remain tdTomato and GFP negative. In contrast, supplementing CLZ3 cells with doxycycline turns on the I-SceI expression ([Figure 1C](#fig1){ref-type="fig"}), resulting in the induction of DSBs on the dual-reporter cassette. Successful repair by HR leads to functional tdTomato, therefore turning cells red, while NHEJ restores active GFP, turning cells green ([Figure 1A--B](#fig1){ref-type="fig"}). Indeed, using the CLZ3 cell line we found that adding doxycycline into the culture medium leads to the I-SceI expression ([Figure 1C](#fig1){ref-type="fig"}), and we observed both tdTomato^+^ (4.3%) and GFP^+^ cells (1.5%) either using confocal microscopy or FACS analysis ([Figure 1D--E](#fig1){ref-type="fig"}). These data indicate that we successfully obtained the cells for screening compounds that potentially alter the balance between HR and NHEJ.

The identification of farrerol as an enhancer of HR but not NHEJ using the CLZ3 cell line {#s2-2}
-----------------------------------------------------------------------------------------

We then employed the CLZ3 cell line to screen a library containing 722 small molecules isolated from herbs used in traditional Chinese medicine. CLZ3 cells were seeded at a density of 10,000 cells per well into a 12-well plate. On day 1 post seeding, cells were supplemented with the chemical compounds at a concentration of 5 μM. On day 2, doxycycline was then added into the culture medium at a concentration of 0.5 µg/mL. On day 4 post splitting, cells were harvested for FACS analysis of DSB repair efficiency ([Figure 1F](#fig1){ref-type="fig"}). Among the 722 screened compounds, we found that it was farrerol that could significantly improve HR repair but had no detectable effect on NHEJ ([Figure 1G](#fig1){ref-type="fig"}). We further validated its stimulatory effect on HR using our well-established HCA2-H15c and HCA2-I9a cell lines for analyzing HR and NHEJ efficiency separately ([@bib24]). Consistent with our observation in CLZ3 cells, farrerol was proved to significantly promote HR and had no obvious influence on NHEJ in these cell lines ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In addition, using the extrachromosomal assay we also demonstrated that farrerol significantly promoted HR repair efficiency in mouse ESCs ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

To elucidate the molecular mechanisms of HR activation by farrerol, the protein levels of HR associated factors including RPA2, NBS1, RAD50, RAD51, MRE11, CtIP, BRCA1, EXO1 XRCC2, and 53BP1, a negative regulator of HR, were analyzed by western blot ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). We did not observe any significant alterations in the expression level of repair-related factors upon farrerol treatment, indicating that enhancement of HR efficiency is probably not due to changes in the expression levels of the analyzed HR factors. Similarly, cell cycle distribution was not significantly impacted by farrerol treatment ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), suggesting that the promotion of HR by farrerol is not through arresting cells in the HR-dominant S/G2 stage. We then hypothesized that farrerol might improve HR by accelerating the recruitment of HR factors to DNA damage sites. Accordingly, we checked the recruitment of RPA2, a single-strand DNA binding protein, at indicated time points post 2 Gy ionizing irradiation (IR) using immunofluorescence assay ([Figure 1---figure supplement 2C--D](#fig1s2){ref-type="fig"}). However, the result indicated that farrerol has no influence on the recruitment of RPA2. Surprisingly, we found that the average foci number of RAD51 per nucleus was 6.5 and 6.1 in the presence of farrerol (1 and 5 μM) at 4 hr post IR at 2 Gy, in comparison to 4.4 in control group ([Figure 1---figure supplement 2E--F](#fig1s2){ref-type="fig"}). At 16 hr post IR, the average foci number of RAD51 per nucleus dropped to 3.2 and 4.3 in farrerol treating cells whereas there were still 6.4 RAD51 foci in the control group ([Figure 1---figure supplement 2E--F](#fig1s2){ref-type="fig"}). These data indicate that the rapid recruitment and timely clearance of RAD51 post IR may contribute to the promotion of HR by farrerol.

In mammalian cells HR can be further categorized into precise gene conversion, crossover, and the SSA pathway which results in deletions of DNA sequences between two direct repeats ([@bib16]). We tested whether farrerol potentially affects SSA, thereby causing a loss of genome integrity. We employed two previously reported reporters HRF, which measures the efficiency of gene conversion, crossover and SSA ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}), and HRIF, which measures only gene conversion and crossover ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}). Therefore, SSA efficiency can be quantified with HRF minus HRIF ([@bib26]). The two reporters were integrated into HCA2-hTERT cells, and a pool of colonies containing chromosomally integrated reporters were mixed for further analysis. Consistent with a previous report that RAD51 is not involved in SSA pathway ([@bib2]; [@bib3]; [@bib28]), we found that activating RAD51 with RS-1 had no effect on SSA efficiency. Surprisingly, treating cells with farrerol significantly suppressed SSA efficiency by 3.3-fold and 1.9-fold at concentrations of 5 μM and 10 μM respectively ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}), suggesting that farrerol might help maintain genome integrity by avoiding the aberrant recombination between the abundant repetitive sequences across genomes.

Farrerol promotes the efficiency of SpCRISPR/Cas9-mediated gene targeting in HEK 293FT cells {#s2-3}
--------------------------------------------------------------------------------------------

Precisely inserting an exogenous gene into a specific locus requires efficient and faithful HR directed repair ([@bib31]). We therefore set out to examine whether farrerol enhances the efficiency of SpCRISPR/Cas9-mediated gene targeting. HEK 293FT cells were pretreated with farrerol or two positive control compounds SCR7 ([@bib8]; [@bib18]) and RS-1 ([@bib36]) at the indicated concentrations for 24 hr, followed by co-transfection with vectors encoding Cas9 and sgRNA targeting the *AAVS1* site, and a donor plasmid containing a promoter-less puromycin and a GFP gene driven by the CAG promoter ([Figure 2A](#fig2){ref-type="fig"}). At 48 hr post transfection, cells were supplemented with 1 μg/mL puromycin, and puromycin-resistant and GFP^+^ colonies were then quantified ([Figure 2B--C](#fig2){ref-type="fig"}). We further analyzed the knock-in efficiency using PCR with primers as indicated ([Table 1](#table1){ref-type="table"}; [Figure 2A](#fig2){ref-type="fig"}). We found that farrerol significantly stimulated the knock-in efficiency by \~2.0 fold at the concentration of 1 and 5 µM, which was similar to those of RS-1 or SCR7 treatment ([Figure 2D--E](#fig2){ref-type="fig"}). In addition, we did not observe any significant effect on cell proliferation in the presence of farrerol at the indicated concentrations ([Figure 2F](#fig2){ref-type="fig"}), suggesting a low toxicity of this compound.

###### PCR primer sequences.

Table 1---source data 1.PCR primer sequences.

  Target name   Primer name       Sequence (5\'\>3\')       Description    Reference
  ------------- ----------------- ------------------------- -------------- ---------------------------------------------------------------
  *AAVS1*       HR-AAVS1-F        gccgtctctctcctgagt        Primer 1\#     PMID:[23287722](https://www.ncbi.nlm.nih.gov/pubmed/23287722)
  *AAVS1*       HR-Puro-R         gtgggcttgtactcggtcat                     
  *AAVS1*       GFP-F             acgtaaacggccacaagttc      Primer 2\#     This paper
  *AAVS1*       GFP-R             gaactccagcaggaccatgt                     
  *Actb*        mActb-HR-F        ccatctacgagggctatgct      5\' junction   This paper
  *Actb*        mActb-HR-R        gtgggcttgtactcggtcat                     
  *Actb*        3\' Actb-puro-F   gtgtctctcactcggaaggac     3\' junction   
  *Actb*        3\'inner-R        gcctaggtttctggaggagt                     
  *Actb*        5\'outer-F        ccctgagtgtttcttgtggc      5\' junction   PMID:[28524166](https://www.ncbi.nlm.nih.gov/pubmed/28524166)
  *Actb*        5\'outer-R        tggagccgtacatgaactga                     
  *Actb*        5\'inner-F        ccatctacgagggctatgct                     
  *Actb*        5\'inner-R        tgaagcgcatgaactccttg                     
  *Actb*        3\'outer-F        gccccgtaatgcagaagaag      3\' junction   
  *Actb*        3\'outer-R        aggtagtgttagtgcaggcc                     
  *Actb*        3\'inner-F        ctacgacgctgaggtcaaga                     
  *Actb*        3\'inner-R        gcctaggtttctggaggagt                     
  *Cdx2*        5\'outer-F        acttggacagagaaagagcgatt   5\' junction   PMID:[28524166](https://www.ncbi.nlm.nih.gov/pubmed/28524166)
  *Cdx2*        5\'outer-R        tccatgtgcaccttgaagc                      
  *Cdx2*        5\'inner-F        aacaaaggtccagtctacgcat                   
  *Cdx2*        5\'inner-R        ggccatgttatcctcctcgc                     
  *Cdx2*        3\'outer-F        gacggccccgtaatgcagaa      3\' junction   
  *Cdx2*        3\'outer-R        tagcttgcaaccagagaagatgt                  
  *Cdx2*        3\'inner-F        ctacgacgctgaggtcaaga                     
  *Cdx2*        3\'inner-R        cgacttcccttcaccatacaac                   

![Farrerol promotes SpCRISPR/Cas9-mediated knock-in efficiency in human cells.\
(**A**) Schematic diagram of the gene targeting strategy at the human *AAVS1* locus. A donor vector containing a promoter-less p2A-puromycin and GFP gene driven by the CAG promoter was designed for targeting the *AAVS1* locus. The underlined trinucleotide represents the PAM, and the sgRNA targeting site is labeled in blue. Puro stands for puromycin. Two pairs of primers used for genotyping are indicated by arrows. The length of the left and right homologous arm is 804 bp and 837 bp, respectively. Primer sequences are listed in the [Table 1](#table1){ref-type="table"}. (**B**) Workflow of gene targeting at the *AAVS1* locus in HEK 293FT cells. (**C**) Representative microscopy images of successfully targeted GFP^+^ HEK 293FT cells post 1 μg/mL puromycin selection. (**D--E**) Effect of different small molecules on gene knock-in frequency at the human *AAVS1* locus. The surviving colonies post puromycin selection were further validated by genotyping using PCR. (**F**) Growth curve of HEK 293FT cells treated with the indicated doses of farrerol. For (**D**) and (**E**), χ^2^-test was used for statistical analysis. Error bars in (**F**) represent the s.d. and t-test was used for statistical analysis. \*p\<0.05, \*\*p\<0.01, n.s., not significant. All experiments were repeated at least three times.\
Figure 2---source data 1.Summary of knock-in efficiency in HEK 293FT cells.](elife-56008-fig2){#fig2}

More strictly, we further examined whether farrerol could improve the efficiency of SpCRISPR/Cas9-mediated gene targeting using a different targeting vector. The p2A-mCherry-WPRE-polyA vector was then generated which also targeted the *AAVS1* locus ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Knock-in efficiency was measured by scoring the number of mCherry^+^ cells with FACS ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Consistently, we found that farrerol could significantly improve the targeting efficiency in this system at concentrations ranging from 0.1 μM to 10 μM ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}).

Taken together, these data reveal that farrerol improves knock-in efficiency in HEK 293FT cells.

Farrerol promotes SpCRISPR/Cas9-mediated gene knock-in in mouse ESCs {#s2-4}
--------------------------------------------------------------------

Because efficient gene targeting in ESCs holds great potential for further application in both basic research and clinical medicine, we set out to test whether farrerol could enhance the efficiency of SpCRISPR/Cas9-mediated insertions in mouse ESCs. We first examined the insertion efficiency at the *Actin β* (*Actb*) locus, using an sgRNA as previously described ([@bib51]). Mouse ESCs were pretreated with farrerol, SCR7 or RS-1 for 24 hr, followed by a co-transfection with vectors encoding Cas9, sgRNA targeting the *Actb* site, and a donor plasmid containing a promoter-less p2A-puromycin and GFP gene driven by the CAG promoter ([Figure 3A](#fig3){ref-type="fig"}). Successful insertion mediated by HR directed repair in this system results in an *Actb*-puromycin-CAG-GFP fusion protein, converting cells to puromycin resistant and GFP positive. Then, these puromycin-resistant colonies could be stained with Coomassie blue and counted to score insertion efficiency ([Figure 3B](#fig3){ref-type="fig"}). Meanwhile, GFP^+^ colonies could be observed under the fluorescence microscope ([Figure 3C](#fig3){ref-type="fig"}). Strikingly, we found that treating cells with an increasing concentration of farrerol significantly promoted knock-in efficiency by as high as 2.8-fold (10 μM) while both SCR7 and RS-1 had only mild effects on insertion efficiency ([Figure 3D](#fig3){ref-type="fig"}). Furthermore, we picked individual mouse ESC colonies, and confirmed the correct insertion into the *Actb* locus by PCR and Sanger sequencing ([Figure 3E](#fig3){ref-type="fig"}). Together, these data demonstrate that farrerol dramatically stimulates the efficiency of SpCRISPR/Cas9-mediated gene targeting into *Actb* locus of mouse ESCs.

![Farrerol promotes SpCRISPR/Cas9 mediated gene targeting efficiency in mouse ESCs.\
(**A**) Schematic diagram of the gene targeting strategy at the mouse *Actb* locus. A donor vector containing a promoter-less p2A-puromycin (Puro) and GFP gene driven by the CAG promoter was designed for targeting the mouse *Actb* locus. The underlined trinucleotide represents the PAM, and the sgRNA targeting site is labeled in red. The length of the left and right homologous arm is 801 bp and 800 bp, respectively. (**B**) Representative images of Coomassie blue stained puromycin resistant E14 cells which were successfully knocked in. Transfection of donor only or the mixture of sgRNA and Cas9 were set as the negative control. (**C**) Representative microscopy images of successfully targeted E14 cells with GFP expression. (**D**) Effect of different small molecules on gene targeting frequency at the *Actb* locus in mouse ESCs. The knock-in efficiency was measured by counting the cell colonies which were resistant to puromycin. (**E**) The Sanger sequencing results of the 5' and 3' junction regions of successfully knocked-in cells treated with farrerol. HAL stands for the left homologous arm and HAR stands for the right homologous arm. Error bars represent the s.e.m. \*\*p\<0.01, \*\*\*p\<0.001, n.s., not significant, t-test. All experiments were repeated at least three times.\
Figure 3---source data 1.Summary of knock-in efficiency in mouse ESCs.](elife-56008-fig3){#fig3}

In addition to the *Actb* locus, we further tested if pretreatment of farrerol facilitated the SpCRISPR/Cas9-mediated targeting into two other loci, *Rosa26* and *Sox2*. A p2A-BFP-WPRE donor was designed to target the *Rosa26* locus in mouse ESCs ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). On day three post transfection of plasmids containing the donor and Cas9 along with sgRNA targeting the *Rosa26* site, the percentage of BFP^+^ cells was measured by FACS. Consistently, treating cells with farrerol significantly improved knock-in efficiency, with the largest increase of 2.9-fold observed at the concentration of 5 μM ([Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}). Additionally, a 2.0-fold improvement in knock-in efficiency at the *Sox2* site could be observed after farrerol treatment at the concentration of 5 μM, by examining with a previously reported p2A-mCherry donor ([@bib51]; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Collectively, farrerol can efficiently promote HR at multiple loci in mouse ESCs.

Farrerol has no obvious adverse effects on genomic stability in human fibroblasts or mouse ESCs {#s2-5}
-----------------------------------------------------------------------------------------------

To investigate whether treating cells with farrerol would lead to a destabilized genome, we first performed immunostaining experiments with antibodies against γH2AX and 53BP1 to examine the potential genotoxic side effects of each small molecule. We observed a mild decrease in γH2AX foci number or fluorescence intensity, and no obvious change in 53BP1 foci number in farrerol-treated HCA2-hTERT fibroblasts or mouse ESCs ([Figure 4A--D](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). However, treating cells with SCR7 and RS-1 resulted in the increase of the percentage of γH2AX positive cells, suggesting the genotoxic side effects of these two molecules on cells ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). Comet assay was also performed to examine if farrerol had any negative effect on genome integrity, and no significant change was noticed in the presence of farrerol ([Figure 4E](#fig4){ref-type="fig"}). By contrast, although fairly mild, we observed a significant increase in genomic instability in mouse ESCs treated with SCR7 ([Figure 4E](#fig4){ref-type="fig"}), which inhibits the NHEJ pathway. To further explore the potential influence of drug treatment on large-scale chromosomal rearrangements, we further performed karyotyping analysis. The result showed that farrerol treatment had no obvious influence on the karyotype of mouse ESCs after gene editing. And more surprisingly, treating mouse ESCs with SCR7 or RS-1 for only 48 hr caused a significant decrease in the percentage of cells with normal karyotypes ([Figure 4F](#fig4){ref-type="fig"}). Furthermore, we also performed EdU incorporation experiments to examine if farrerol affected DNA replication in mouse ESCs. In agreement with the analysis in HEK 293FT cells ([Figure 2F](#fig2){ref-type="fig"}), we did not observe any significant change in DNA replication in mouse ESCs ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

![The effects of small molecule treatment on genomic stability in mouse ESCs.\
(**A**) Representative images of γH2AX immunostaining in mouse ESC E14 treated with indicated doses of small molecules. (**B**) Analysis of relative intensity of γH2AX in mouse ESCs in (**A**). The results were normalized to those in control group. Each dot represents the relative fluorescence intensity of a single nucleus. (n ≥ 180 single nucleus). (**C**) Representative images of 53BP1 immunostaining in mouse ESC E14 treated with indicated doses of small molecules. (**D**) Quantification of 53BP1 foci numbers in (**C**). At least 50 cells were included for each group. (**E**) Representative images of alkaline comet assay of mouse ESC E14 treated with indicated doses of molecules for 24 hr (left panel). The tail moments of at least 50 cells for each group were quantified using Cometscore software (Sumerduck, VA, USA) (right panel). (**F**) Karyotyping analysis indicated that 48 hr farrerol treatment post spCRSIPR/Cas9 mediated editing did not greatly affect karyotypes (40, XY) of the Oct4-ΔPE-GFP transgenic C57BL/6 × PWK ESCs. Error bars in (**B**), (**D**) and (**E**) represent the s.e.m. Error bars in (**F**) represent the s.d. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s., not significant, t-test.\
Figure 4---source data 1.The genotoxicity of small compounds treatment.](elife-56008-fig4){#fig4}

In summary, these results indicate that farrerol is a safe compound when used to improve the efficiency of precise genome integration.

Farrerol effectively promotes targeted integration and supports the efficient generation of gene-targeting mice with germline transmission {#s2-6}
------------------------------------------------------------------------------------------------------------------------------------------

To further test the utility of farrerol in the embryo system and whether it could facilitate the generation of gene targeted animals, we first examined its potential toxicity. Mouse zygotes were cultured in media containing either farrerol, RS-1 or SCR7, and we then examined whether these compounds had any impact on the *in vitro* development potential of mouse embryos. We found that farrerol could fully support the mouse embryos through the hatching of blastocysts as did control and RS-1; by contrast, SCR7 treatment significantly impaired the blastocyst production rate ([Figure 5A--B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Considering the SpCRISPR/Cas9-mediated cleavage of DNA and the subsequent HR directed repair occurs and is primarily completed during the 1 cell to 2 cell stage, we then cultured the mouse zygotes in the indicated small molecule containing media through the late 2 cell stage. The results indicated that short-period treatment with the three compounds had nearly no effect on the early embryo development and more than 95% of the 2 cell embryos could develop into the blastocyst stage ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). However, during the zygotes stage where DSBs were induced due to the injection of Cas9 mRNA and sgRNA targeting the *Cdx2* locus, treatment with the three compounds yielded different results. Only 62.5% of SCR7 treated embryos could develop into the blastocyst stage, probably due to the inhibition of NHEJ. By contrast, farrerol treated embryos showed an 82.4% blastocyst production rate ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}).

![Farrerol promotes gene targeting in mouse embryos.\
(**A**) *In vitro* development potential of mouse embryos treated with indicated doses of compounds during the whole embryonic stages. (**B**) The development rate of hatching blastocysts at E4.5 treated with indicated doses of compounds. The data is related to (**A**). (**C**) Effect of compounds treatment for 24 hr on *in vitro* development potential of mouse embryos upon DSBs were induced by Cas9 mRNA and sgRNA targeting the *Cdx2* locus. (**D**) Schematic diagram of the gene targeting strategy at the *Actb* locus in mouse embryos. A donor vector containing a promoter-less p2A-mCherry was designed for targeting the *Actb* locus. The underlined trinucleotide represents the PAM, and the sgRNA targeting site is labeled in red. The length of the left and right homologous arm is 801 bp and 800 bp, respectively. (**E**) Diagram of the methods for gene targeting efficiency analysis in mouse blastocysts. (**F**) Representative fluorescence images of gene-edited mouse embryos at the *Actb* locus at the blastocyst stage. (**G--H**) Effect of indicated small compounds on gene knock-in frequencies at the *Actb* locus. Knock-in frequency was indicated by the percentage of mCherry^+^ blastocysts in (**G**), and was confirmed by PCR genotyping analysis using primers amplifying the flanks of the *Actb* site in (**H**). Number above each bar, total blastocysts analyzed. Error bars in (**A**), (**B**) and (**C**) represent the s.d. and t-test was used for statistical analysis. For (**G**) and (**H**), χ^2^-test was used for statistical analysis. \*p\<0.05, \*\*p\<0.01, n.s., not significant.\
Figure 5---source data 1.Summary of knock-in efficiency in blastocysts.](elife-56008-fig5){#fig5}

To further investigate whether farrerol could improve knock-in efficiency in mouse embryos, we injected Cas9 mRNA, sgRNA targeting the *Actb* gene and p2A-mCherry donor cassette into mouse zygotes ([Figure 5D--E](#fig5){ref-type="fig"}; [@bib51]). Then the injected zygotes were treated with farrerol at a concentration of 0 (control), 0.05 μM, 0.1 μM, or SCR7 (20 μM), RS-1 (7.5 μM) as previously reported ([@bib42]). At late 2 cell stage, these embryos were picked out and cultured in normal media until the blastocyst stage, and the integration efficiencies were assessed by mCherry^+^ fluorescence at E4.5 ([Figure 5F](#fig5){ref-type="fig"}). Interestingly, a much higher rate of mCherry^+^ blastocysts was observed in the presence of farrerol (0.05 μM, 27.3%; 0.1 μM, 21.0%), than in the control treatment (14.0%) ([Figure 5F--G](#fig5){ref-type="fig"}). Importantly, this efficiency is comparable to or even higher than that mediated by HMEJ (Homology-mediated end joining, 22.7%) and MMEJ (Microhomology-mediated end joining, 11.9%) donors ([@bib51]). By contrast, the knock-in efficiency was only slightly improved after SCR7 (19.2%) or RS-1 (16.5%) treatment, which is in agreement with a recent study ([@bib42]). We then examined the integration fidelity by genotyping the integration sites of individual blastocysts. Consistently, PCR amplification of both the 5' and 3' junctions revealed that farrerol treatment led to a higher in-frame integration rate (farrerol: 0.05 μM, 27.0%; 0.1 μM, 23.0%) in comparison to the control group (13.0%). However, treatment with SCR7 (15.1%) or RS-1 (17.8%) were shown to have limited effect ([Figure 5H](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}).

To rule out the possibility that the promotion of the SpCRISPR/Cas9-mediated genome targeting efficiency is position-dependent in mouse embryos, we further examined the knock-in efficiency at the *Cdx2* locus, by fusing a p2A-mCherry cassette to the C-terminus of the trophectoderm (TE) marker gene ([Figure 6A](#fig6){ref-type="fig"}). Successful integration into *Cdx2* locus results in mCherry positivity, which can be observed in trophoblast cells in the blastocyst. Embryos treated by farrerol showed a repeatable and remarkable increase of mCherry^+^ fluorescence signals in TE by 57.4% (0.05 μM) and 68.3% (0.1 μM) in comparison to that in control group. As a comparison, SCR7 and RS-1 improved the targeting efficiency by 54.3% and 37.4% respectively ([Figure 6B--C](#fig6){ref-type="fig"}). Genotyping analysis further confirmed the capacity of farrerol to robustly stimulate SpCRISPR/Cas9-mediated gene editing ([Figure 6D](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}).

![Farrerol promotes the generation of gene-targeted mice with germline transmission.\
(**A**) Schematic diagram of the gene targeting strategy at the *Cdx2* locus in mouse embryos. A donor vector containing a promoter-less p2A-mCherry was designed for targeting the *Cdx2* locus. The underlined trinucleotide represents the PAM, and the sgRNA targeting site is labeled in brown. The length of both the left and right homologous arm are 800 bp. (**B**) Representative fluorescence images of gene-edited mouse embryos at the *Cdx2* locus at the blastocyst stage. (**C--D**) Effect of different small molecules treatment on gene knock-in frequency at the *Cdx2* locus. Knock-in frequency was indicated by the percentage of mCherry^+^ blastocysts in (**C**), and was confirmed by PCR genotyping analysis using primers amplifying the flanks of the *Cdx2* site in (**D**). Number above each bar, total blastocysts analyzed. (**E**) Effect of different knock-in strategies on generation of gene-targeting mice. The microinjected 2 cell stage embryos with or without farrerol treatment was transplanted into the pseudo-pregnant mice. The HMEJ mediated knock-in assay was applied as a control. The founder mice were genotyped for gene-targeting frequency analysis. The germline transmission abilities of founder mice were also validated. (**F**) Representative fluorescence images of blastocysts from homozygous *Cdx2*-mCherry mice. (**G**) Representative fluorescence images of *Cdx2* mCherry signals in embryos at the stage of E7.5 and E9.5 after homozygous *Cdx2*-mCherry mice mating with wild-type mice. \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001, n.s., not significant, χ^2^-test.\
Figure 6---source data 1.Generation of gene-targeted mice with germline transmission.](elife-56008-fig6){#fig6}

In order to test if farrerol potentially affected the late stages of embryonic development and the generation of knock-in mice, we transplanted farrerol-treated microinjected 2 cell stage embryos into pseudo-pregnant mice ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). In the farrerol treated group, 12 out of 33 mice showed an in-frame integration (36.4%; potential founders \#1, \#2, \#3, \#7, \#9, \#16, \#18, \#21, \#23, \#26, \#27, \#32), which was confirmed by the PCR amplification of both the 5' and 3' junctions at *Cdx2* locus ([Figure 6E](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Sanger sequencing data further supported this conclusion ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). By contrast, only one knock-in mouse was identified in a total 53 mice generated in control group. In addition, as a further comparison, no knock-in mice were detected by using the HMEJ donor ([@bib51]; [Figure 6E](#fig6){ref-type="fig"}). Moreover, *Cdx2*-mCherry mice generated from farrerol treated embryos had germline transmission abilities and the allele with the exogenous gene knocked in could be stably transmitted to the progeny generation (F1) with Mendel's law of segregation, after being crossed with wild-type C57BL/6 mice ([Figure 6E](#fig6){ref-type="fig"}). Furthermore, homozygous *Cdx2*-mCherry mice could be successfully produced and maintained. And all the blastocysts from these mice after crossing showed the strong mCherry^+^ fluorescence signals in the trophectoderm ([Figure 6F](#fig6){ref-type="fig"}). At the E7.5 stage, these mCherry signals were restricted to extraembryonic ectoderm (ExE) ([Figure 6G](#fig6){ref-type="fig"}). At the stage of E9.5, *Cdx2* mCherry signals could be observed in embryonic tissues, principally in the posterior part of the gut, tail bud and the caudal part of the neural tube as previously reported ([Figure 6G](#fig6){ref-type="fig"}; [@bib1]).

Since the glycoprotein matrix, termed the zona pellucida (ZP), surrounding mammalian eggs physically separates the embryo from the external environment which may restrict the actual working concentration of this small molecule, we then asked whether the integration efficiency could be further improved by direct injection of farrerol into the cytoplasm of the zygote. Thus, small molecules (farrerol at final concentration of 0.05 μM, 0.1 μM; SCR7 at final concentration of 1 μM; RS-1 at final concentration of 7.5 μM) were individually added to the CRISPR/Cas9 mixture (Cas9 mRNA, sgRNA and donor) for microinjection into the zygotes and the injected embryos were cultured in normal medium into blastocysts. Intriguingly, in comparison to control group, we observed a significantly increased rate of gene editing at the *Actb* site (0.05 μM, by 2.3-fold; 0.1 μM, by 2.6-fold) and *Cdx2* locus (0.05 μM, by 2.0-fold; 0.1 μM, by 2.3-fold) after co-injection of farrerol, while co-injecting the other two compounds had mild effects on integration efficiency ([Figure 6---figure supplement 2A--B](#fig6s2){ref-type="fig"}). The genotyping analysis further confirmed that farrerol could promote gene editing at these two genomic loci ([Figure 6---figure supplement 2C--D](#fig6s2){ref-type="fig"}).

Cumulatively, these results demonstrate that farrerol can enhance in-frame integration of exogenous donor DNA and efficiently generate knock-in mice with germline transmission capacity.

Discussion {#s3}
==========

Recently developed exogenous enzyme-based genome editing tools have greatly improved the efficiency of gene knock-out as the generated DSBs can be repaired by the error-prone and cell cycle-independent NHEJ pathway, resulting in non-functional genes ([@bib12]; [@bib22]). In contrast, precisely knocking genetic material into an endogenous locus requires an active HR pathway, which is not a predominant DSB repair pathway in human cells ([@bib24]; [@bib25]). Therefore, promoting HR directed repair or suppressing the NHEJ pathway have been explored as tools for improving the efficiency of SpCRISPR/Cas9-mediated gene targeting ([@bib41]). Quite different from other screening platforms applied for searching for gene targeting activators, here, we created the screening platform based on DSB repair outcomes. The advantages of this system are that (1) it does not require any transfection of exogenous genes, and therefore avoids any potential interference resulting from transfections, such as changes in cell cycle stages, in which DSB repair pathways differ; (2) it can be easily scored either on FACS or on a high throughput automated high-content IN Cell imaging system; (3) the screened compounds affecting the efficiency of the two DSB repair pathways can be applied to other purposes including targeting cancer alone or in combination with other therapeutic methods, and delaying the onset of aging by improving genome integrity.

Our data clearly indicate that farrerol promotes HR through facilitating the recruitment of RAD51, the critical recombinase involved in HR, to DSB sites, but has no obvious effect on NHEJ. This result explains our observation that farrerol promotes SpCRISPR/Cas9-mediated targeting efficiency at different genomic loci in different cell types, indicating that farrerol holds great potential in applications related to SpCRISPR/Cas9-mediated genome editing. Among a number of compounds that stimulate the efficiency of gene targeting, RS-1 and SCR7 are the best-characterized and the most commonly used. RS-1 physically interacts with RAD51 to promote HR ([@bib14]). Surprisingly, the promotion of gene targeting by RS-1 is dependent on the size of the homologous arm of the targeting vectors ([@bib30]; [@bib31]), and the type of cells ([@bib42]; [@bib55]). It is hypothesized that the promotion of gene targeting by SCR7 is through suppressing the canonical NHEJ (c-NHEJ) pathway by blocking the enzymatic activity of DNA LIG4, forcing cells to choose the other DSB repair pathway -- HR ([@bib11]; [@bib43]). Although some of our results confirmed previous findings that supplementing SCR7 improves the efficiency of gene targeting ([@bib27]; [@bib40]; [@bib42]), the effects are rather mild and it does not always function at the given genomic locus or in different types of cells. This can be explained by the fact that in addition to c-NHEJ and HR, alternative NHEJ (alt-NHEJ) can also repair DSBs. Treating cells with SCR7 actually leaves DSBs repaired either by HR and alt-NHEJ. Whether an optimized treatment with farrerol -- such as concentration, treatment time or combinations of these compounds can further improve gene targeting efficiency remains to be further determined. Moreover, a comprehensive and thorough study on the mechanism by which farrerol promotes HR would also help the future application of this compound in genome editing.

Since HR and NHEJ are two competitive pathways when repairing DSBs particularly in the S/G2 phase with sister chromatids available ([@bib25]), why does not the activation of HR pathway by farrerol cause the decrease in NHEJ? Upon DSB induction, several consequences might occur: (1) DSBs are not repaired and cells undergo cellular senescence or apoptosis; (2) DSBs are repaired by canonical NHEJ or alternative NHEJ; (3) DSBs are repaired by three sub-pathways of HR, gene conversion, crossover and SSA. Since we also observed that farrerol suppresses the mutagenic SSA pathway, it is possible that without affecting the two sub-NHEJ pathways, farrerol promotes the two precise HR pathways -- gene conversion and crossover -- by suppressing SSA pathway. Another possibility is that farrerol might tip cells with DSBs away from entering senescence or apoptosis and towards DSB repair by HR.

Safety is one of the most noteworthy issues in the field of genome editing. Our data suggest that farrerol exhibits no detectable adverse effect on the normal development of mouse blastocysts *in vitro*. More importantly, healthy founder mice with the precise genomic edit of interest could be efficiently generated, and the edited allele could be successfully transmitted to their offspring. Although some literature has reported that high concentration of SCR7 treatment increased the HR efficiency by as much as 10-fold in mouse embryos ([@bib40]) and mammalian cells ([@bib18]), our data indicated that SCR7 at such a high concentration would lead to adverse effects on karyotype and blastocyst development. The reason might lie in that inhibiting c-NHEJ might lead to inefficient and late repair of DSBs ([@bib6]; [@bib46]), resulting in abnormal development. In addition, blocking c-NHEJ may destabilize genomes, increasing the incidence of tumorigenesis and the onset of premature aging ([@bib6]; [@bib39]; [@bib47]). Moreover, the further application of compounds activating HR directed repair should also be cognizant of the possibility that aberrantly activated HR might be beneficial to tumor cells, and may disrupt the genome integrity by aberrantly recombining the abundantly available repetitive sequences across the genomes in normal cells ([@bib33]; [@bib38]). For instance, increased expression of RAD51 destabilizes genomes by stimulating aneuploidy and making chromosomal rearrangements more likely ([@bib35]). Future studies on whether and how a short-term treatment of RS-1 or farrerol affects genome integrity are still warranted.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                 Source or\                                                                         Identifiers                                                      Additional\
  (species) or\                                                                                reference                                                                                                                                           information
  resource                                                                                                                                                                                                                                         
  ------------------------------------------------ ------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Genetic reagent (*M. musculus*)                  C57BL/6n                                    Beijing Vital River Laboratory                                                     Stock No.: 213                                                   

  Genetic reagent (*M. musculus*)                  ICR                                         Beijing Vital River Laboratory                                                     Stock No.: 201                                                   

  Genetic reagent (*M. musculus*)                  BDF1                                        This paper                                                                         /                                                                The BDF1 hybrid mice were obtained from mating female C57BL/6n mice with male DBA/2 mice.

  Genetic reagent (*M. musculus*)                  DBA/2                                       Beijing Vital River Laboratory                                                     Stock No.: 214                                                   

  Genetic reagent (*M. musculus*)                  PWK/PhJ                                     Jackson Laboratory                                                                 Stock No.: 003715                                                

  Gene (*Homo sapiens*)                            *AAVS1*                                     GenBank                                                                            GeneID: 54776                                                    

  Gene (*M. musculus*)                             *Actb*                                      GenBank                                                                            GeneID: 11461                                                    

  Gene (*M. musculus*)                             *Sox2*                                      GenBank                                                                            GeneID: 20674                                                    

  Gene (*M. musculus*)                             *Rosa26*                                    GenBank                                                                            GeneID: 14910                                                    

  Gene (*M. musculus*)                             *Cdx2*                                      GenBank                                                                            GeneID: 12591                                                    

  Strain, strain background (*Escherichia coli*)   Trans109                                    TransGen Biotech                                                                   CD301                                                            Competent cells

  Cell line (*Homo sapiens*)                       HCA2-hTERT                                  [@bib10] (doi: [10.1074/jbc.M202671200](https://doi.org/10.1074/jbc.M202671200))                                                                    Human fibroblast

  Cell line(*Homo sapiens*)                        HEK 293FT                                   ATCC                                                                               RRID:[CVCL_6911](https://scicrunch.org/resolver/CVCL_6911)       

  Cell line (*M. musculus*)                        E14                                         ATCC                                                                               RRID:[CVCL_C320](https://scicrunch.org/resolver/CVCL_C320)       Mouse ES cell line

  Cell line (*M. musculus*)                        Oct4-ΔPE-GFP transgenic C57BL/6 × PWK ESC   This paper                                                                                                                                          Mouse ES cell line

  Antibody                                         Anti-RPA2 (Rabbit polyclonal)               Abclonal                                                                           A2189\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2764207](https://scicrunch.org/resolver/AB_2764207)     

  Antibody                                         Anti-NBS1\                                  Cell Signaling Technology                                                          3002\                                                            WB (1:1000)
                                                   (Rabbit)                                                                                                                       RRID:[AB_331499](https://scicrunch.org/resolver/AB_331499)       

  Antibody                                         Anti-RAD50 (Rabbit polyclonal)              Abclonal                                                                           A3078\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2764881](https://scicrunch.org/resolver/AB_2764881)     

  Antibody                                         Anti-RAD51 (Mouse polyclonal)               Abcam                                                                              ab88572\                                                         IF (1:500), WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2042762](https://scicrunch.org/resolver/AB_2042762)     

  Antibody                                         Anti-MRE11 (Rabbit polyclonal)              Abclonal                                                                           A2559\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2764447](https://scicrunch.org/resolver/AB_2764447)     

  Antibody                                         Anti-53BP1 (Rabbit polyclonal)              Cell Signaling Technology                                                          4937S\                                                           IF (1:100), WB (1:1000)
                                                                                                                                                                                  RRID:[AB_10694558](https://scicrunch.org/resolver/AB_10694558)   

  Antibody                                         Anti-CtIP (Rabbit polyclonal)               Abcam                                                                              ab70163\                                                         WB (1:1000)
                                                                                                                                                                                  RRID:[AB_1209429](https://scicrunch.org/resolver/AB_1209429)     

  Antibody                                         Anti-BRCA1 (Rabbit polyclonal)              Abclonal                                                                           A0212\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2757026](https://scicrunch.org/resolver/AB_2757026)     

  Antibody                                         Anti-EXO1 (Rabbit polyclonal)               Abclonal                                                                           A6810\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2767391](https://scicrunch.org/resolver/AB_2767391)     

  Antibody                                         Anti-XRCC2 (Rabbit polyclonal)              Abclonal                                                                           A1800\                                                           WB (1:1000)
                                                                                                                                                                                  RRID:[AB_2763839](https://scicrunch.org/resolver/AB_2763839)     

  Antibody                                         Anti- TUBULIN (Rabbit polyclonal)           Abmart                                                                             M20005\                                                          WB (1:2000)

  Antibody                                         Anti-gamma H2AX (Rabbit polyclonal)         Cell Signaling Technology                                                          9718S\                                                           IF (1:500)
                                                                                                                                                                                  RRID:[AB_2118009](https://scicrunch.org/resolver/AB_2118009)     

  Recombinant DNA reagent                          sgRNA-Cas9 plasmid                          PMID:[28524166](https://www.ncbi.nlm.nih.gov/pubmed/28524166)                                                                                       Kind gift from Hui Yang lab

  Commercial assay or kit                          Click-iT EdU Assay Kit                      Invitrogen                                                                         C10634                                                           

  Commercial\                                      Comet assay                                 Trevigen                                                                           Cat. \# 4250--050 K                                              
  assay or kit                                                                                                                                                                                                                                     

  Chemical compound, drug                          Farrerol                                    Sigma Aldrich                                                                      SML1389                                                          0.05, 0.1, 1, 5, 10 μM

  Chemical compound, drug                          RS-1                                        ApexBio                                                                            C3357                                                            1, 7.5, 10 μM

  Chemical compound, drug                          SCR7                                        Selleck                                                                            S7742                                                            0.1, 1, 20 μM

  Software, algorithm                              ImageJ software                             ImageJ (<http://imagej.nih.gov/ij/>)                                               RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)     

  Software, algorithm                              GraphPad Prism software                     GraphPad Prism (<http://graphpad.com>)                                             RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)     Version 6.0

  Software, algorithm                              CASPLab software                            CASPLab <http://casp.sourceforge.net>                                              RRID:[SCR_007249](https://scicrunch.org/resolver/SCR_007249)     

  Other                                            DAPI stain                                  Abcam                                                                              ab104939                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Construction of plasmids {#s4-1}
------------------------

To create a doxycycline-inducible vector expressing the rare endonuclease, I-SceI, the open reading frame (ORF) of I-SceI enzyme was amplified, and inserted into the *AAVS1*-TRE-GFP-CAG-rtTA vector to replace the GFP gene using SalI and MluI digestion. A hygromycin resistant gene was also amplified and inserted to the vector at the NotI/KpnI site.

To generate an *AAVS1*-mCherry donor vector, the backbone was isolated from an *AAVS1* donor plasmid (*AAVS1*-SA-Puromycin-CAG-GFP) ([@bib23]) by BglII digestion and gel purification. The p2A-mCherry insert was amplified from *Actb*-p2A-mCherry plasmid ([@bib51]). Afterwards, the insert was recombined into the backbone using the ClonExpress MultiS Cloning Kit (Vazyme catalog no.C113).

To generate the puromycin-GFP donor for targeting the site of the mouse *Actb* gene, both homologous arms were amplified from the *Actb*-p2A-mCherry plasmid. They were then subcloned into the donor plasmid (*AAVS1*-SA-Puromycin-CAG-GFP) by replacing the two *AAVS1* homologous arms.

To create the p2A-BFP-WPRE donor for targeting the mouse *Rosa26* locus, the backbone was isolated from a *Rosa26*-GFP donor plasmid by MluI and PmeI digestion and gel purification. The insert BFP-WPRE fragment was amplified from a pCMV-BFP plasmid. Finally, the insertion fragment was recombined into the backbone vector using the ClonExpress MultiS Cloning Kit (Vazyme catalog no.C113).

All the generated constructs were validated by Sanger sequencing.

Generation of small molecule screening platform {#s4-2}
-----------------------------------------------

The MscI linearized doxycycline-inducible I-SceI expression vector was transfected to the previously reported D4a cells ([@bib7]) using the Lonza 4D electroporation machine with DT-130 program. At 24 hr post transfection, 30 μg/mL Hygromycin B was applied to the transfected cells for selection. On day 12, individual colonies were picked and expanded for further study.

Cell culture and transfection {#s4-3}
-----------------------------

HCA2-hTERT fibroblasts and all derived cell lines were cultured in MEM (Sigma) supplemented with 10% FBS (Gibco, Cat. \#: 10270--106),1% penicillin/streptomycin (Gibco, Cat. \#: 15140--122) and 1% NEAA (Gibco, Cat. \#: 11140--050). HEK 293FT cells were maintained in DMEM (Sigma, Cat. \#: D6429) supplemented with 10% FBS (Gibco, Cat. \#: 10270--106) and 1% penicillin/streptomycin (Gibco, Cat. \#: 15140--122). All cells were cultured at 37 °C in a 5% CO~2~ atmosphere.

Mouse ESCs (E14 cells and Oct4-ΔPE-GFP transgenic C57BL/6 × PWK ESC) were maintained in DMEM supplemented with 15% fetal bovine serum, 1% nonessential amino acid, 1% penicillin/streptomycin, 1% nucleosides, 1% L-glutamax, 0.1 mM mercaptoethanol, 1000 U/mL LIF, 1 μM PD0325901 (Selleck) and 3 μM CHIR99021 (Selleck).

HEK 293FT cells and mouse ESCs were transfected using the Lonza 4D electroporation machine according to the manufacturer's instructions. For HEK 293FT cells transfection, 2 × 10^5^ cells were transfected with mixed plasmids (1 μg sg-*AAVS1* vector, 1 μg Cas9 expression plasmid and 1 μg donor plasmid) using CM130 program. For mouse ESCs, program of CG104 was used to transfect cells. Cells were treated with different small molecules for 24 hr before transfection. Farrerol was purchased from Sigma-Aldrich (SML1389). The concentration of small molecules used in cells were as follows: 0.1 μM or 1 μM SCR7 (Selleck) for HEK 293FT and mouse ESCs, and 1 μM or 20 μM SCR7 for mouse embryos. 1 μM or 10 μM RS-1 (ApexBio) for human and mouse cells, and 7.5 μM RS-1 for mouse embryos. 0.05 μM or 0.1 μM farrerol for mouse embryos, and 0.1 μM or 1 μM or 5 μM or 10 μM farrerol for human and mouse cells.

HEK 293FT cell line and mouse ESC E14 were obtained from ATCC. HCA2-hTERT cell line was obtained from Gorbunova lab ([@bib10]). The mouse ESC cell line used in karyotype analysis was derived from Oct4-ΔPE-GFP transgenic C57BL/6 (paternal) × PWK (maternal) blastocyst. All cell lines were routinely tested to ensure that they were mycoplasma free.

Zygote injection, embryo culturing and generation of Knock-in mice {#s4-4}
------------------------------------------------------------------

Zygote injection and culture was performed as previously reported ([@bib56]). Briefly, embryos were isolated from C57BL/6n or BDF1 female mice (6--8 weeks old). The female mice were super ovulated by intraperitoneally injecting with PMSG (5--6 IU) (Pregnant mare serum gonadotropin) and hCG (6--7 IU) (Human choionic gonadotophin), and then mated to C57BL/6n or BDF1 male mice. The zygotes were harvested from oviducts and received the injection of mixed mCherry-donor (100 ng/μL), Cas9 mRNA (100 ng/μL) and sgRNA (70 ng/μL) targeting *Actb* or *Cdx2* locus, then cultured in G1 plus medium (10128, Vitrolife) with small molecules for \~24 hr. Then the embryos were washed and cultured in new G1 plus medium without small molecules till blastocyst stage. In some cases, the zygotes were directly injected with small molecules and CRISPR/Cas9 mixture and cultured in G1 plus medium. The phenotype of embryos was evaluated on a fluorescent microscope and individual blastocysts were then picked for genotyping analysis.

For analysis of the toxicity of small molecules, the mouse zygotes were cultured in G1 plus medium containing individual small molecules till 2 cell stage or blastocyst stage. The *in vitro* developmental potential of these embryos was recorded until E4.5.

For generation of *Cdx2*-mCherry knock-in mice, zygotes were firstly injected with the combination of Cas9 mRNA (100 ng/μL), sgRNA targeting the *Cdx2* locus (70 ng/μL) and donor (HR donor or HMEJ donor, 100 ng/μL). Then the injected embryos were cultured in G1 plus medium (10128, Vitrolife) with or without farrerol (0.05 μM) for about 24 hr. Then, 15--20 2-cell-stage embryos were transferred into the oviduct of a pseudopregnant female ICR mouse. The number of transferred embryos and born pups was recorded. The genotype of each offspring was verified through Sanger sequencing.

Analysis of the genome targeting efficiency {#s4-5}
-------------------------------------------

For the analysis of gene targeting efficiency in HEK 293FT and mouse ESCs, the cells were electroporated with donors in the absence or presence of the indicated compounds. On day two post transfection, cells were treated with 1 μg/mL puromycin for approximately 1 week. Formed colonies were picked and lysed in 20 μL lysis buffer (0.45% NP-40, 2 mg/mL Proteinase K) for 1 hr at 56 °C and 10 min at 95 °C ([@bib18]). The lysates were used as templates for PCR amplification.

For the analysis of gene targeting efficiency in mouse embryos, the procedure was performed as previously reported ([@bib51]). Single embryos were transferred into PCR tubes containing 5 μL buffer G1 (25 mM NaOH, 0.2 mM EDTA, pH 12) and were lysed at 95 °C for 10 min. Then 5 μL buffer G2 (40 mM Tris-Cl, pH 5) was added to the PCR tubes for neutralization as the samples were cooled to the room temperature. The lysates were used as templates for nested PCR with two pairs of primers.

The PCR products were analyzed on 1% agarose gel and the expected bands were purified for sequencing.

Production of Cas9 mRNA and sgRNA {#s4-6}
---------------------------------

The Cas9 mRNA and sgRNA were produced as previously reported ([@bib20]). Briefly, Cas9 mRNA was *in vitro* transcribed using mMESSAGE mMACHINE T7 ultra transcription kit (Ambion, Thermo Fisher Scientific, USA). Meanwhile, sgRNAs were *in vitro* transcribed using MEGA shortscript T7 kit (Ambion, Thermo Fisher Scientific, USA). Both Cas9 mRNA and specific sgRNA were purified according to the standard protocol by phenol:chloroform extraction and ethanol precipitation, and then dissolved in DNase/RNase-free water (Life Technologies).

Comet assay {#s4-7}
-----------

Mouse ESCs were seeded at a density of 1 × 10^5^ cells per well on 6-well plates. On day 2, cells were incubated with compounds at indicated concentrations. On day 3, cells were harvested for the analysis of genomic stability using alkaline comet assay (Trevigen, Gaithersburg, MD, USA, Cat. \# 4250--050 K).

EdU incorporation assay {#s4-8}
-----------------------

Mouse ESCs at a concentration of 2 × 10^5^ per well were seeded on 6-well plates, followed by compound treatment in 24 hr. After the treatment for another 24 hr, cells were incubated with 10 μM EdU for 2 hr at 37 °C. Cells were collected for conducting EdU assay followed by analysis on FACSverse using a Click-iT EdU Assay Kit (Invitrogen, Waltham, MA, USA, C10634).

Immunofluorescence {#s4-9}
------------------

For the immunofluorescence assay, cells cultured on coverslips were fixed with 4% paraformaldehyde for 15 min at room temperature, and washed with PBS for three times. Then the fixed cells were permeabilized with 0.25% Triton X-100 for 10 min, followed by 10 min-PBS washing for three times. Then the cells were blocked with 1% goat serum for 1 hr at room temperature, followed by the incubation with the indicated antibodies including anti-γH2AX (Cell signaling technology, Cat. \#9718S), anti-53BP1 (Cell signaling technology, Cat. \#4937S), anti-RAD51 (Abcam, Cat. \#ab88572) or anti-RPA2 overnight at 4 °C. After washing with PBS for three times, the cells were incubated with the secondary antibody (Abcam, goat-anti-rabbit-FITC, Cat. \#ab6717) for 1 hr at room temperature. Cells were then washed with PBS for three times before covered with mounting medium with DAPI (Abcam, Cat. \#ab104939). The images were taken on a Nikon A1R laser scanning confocal microscope and analyzed with ImageJ.

Karyotyping assay {#s4-10}
-----------------

The karyotype analysis was performed as previously reported ([@bib19]). Briefly, one million Oct4-ΔPE-GFP transgenic C57BL/6 × PWK ESCs were firstly transfected with 3 μg sgRNA-Cas9 plasmid targeting the *Cdx2* locus and 2 μg donor plasmid. At 48 hr post transfection and treatment of indicated compounds, the cells were cultured in mouse ESC medium with 0.25 mg/mL colcemid (Invitrogen, Thermo Fisher Scientific) for 2 -- 3 hr and collected with 0.05% Trypsin-EDTA (Invitrogen, Thermo Fisher Scientific). Then cells were incubated in hypotonic solution containing 0.4% sodium citrate and 0.4% potassium chloride at 37°C for 5 min, and were then fixed with a methanol/acetic acid mixture (3:1, v/v). The fixed cells were mounted on coverslips and stained with Giemsa at 37°C for 10--15 min after drying.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Zhang et al. developed a screening platform using a dual fluorescent reporter for homologous recombination (HR) and non-homologous end joining (NHEJ) activity and report the identification of farrerol, a natural compound isolated from Rhododendron, that specifically enhances HR. The authors report a statistically significant increase in targeted integration using CRISPR-Cas9 mediated DSBs in HEK293 cells at the AAVS1 locus as well as in mouse embryonic stem cells at three different gene loci (*Actb*, *Rosa26*, *Sox2*). The compound does not lead to genotoxic stress as measured by γH2AX and 53BP1 foci and does not lead to karyotypic changes. Moreover, they show increased targeting activity in mouse embryos, which is statistically significant, an increase in germline transmission, and a control for absence of negative effect during embryonic development. The compound is readily commercially available and may substantially increase the efficiency of targeted integration in human and mouse cells, as well as aid in generating knock-in mice.

**Decision letter after peer review:**

Thank you for submitting your article \"A high-throughput small molecule screen identifies farrerol as a potentiator of CRISPR/Cas9-mediated genome editing\" for consideration by *eLife* as a Tools and Resources article. Your article has been reviewed by two peer reviewers, including Wolf-Dietrich Heyer as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \'in revision at *eLife*\'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

The manuscript describes the development of a screening platform using a dual fluorescent reporter on homologous recombination (HR) and non-homologous end joining (NHEJ) activity and the identification of farrerol, a natural compound isolated from Rhododendron, that appears to specifically enhance HR. The authors show that this compound enhances the HR signal by about 2.5-fold, whereas the NHEJ signal remains unchanged. They show a statistically significant increase in targeted integration using CRISPR-Cas9 mediated DSBs in HEK293 cells at the *AAVS1* locus as well as in mouse embryonic stem cells at three different gene loci (*Actb*, *Rosa26*, *Sox2*). Moreover, they show increased targeting activity in mouse embryos, which is statistically significant, an increase in germline transmission, and control for absence of negative effect during embryonic development. The compound is readily commercially available and may substantially increase to efficiency of targeted integration in human and mouse cells, as well as aid in generating knock-in mice.

Essential revisions:

1\) The screening platform and the dual reported system is not explained well in Figure 1 and needs substantial clarification. In A, what does SA and SD is not defined. How long is the homology for the HR assay part? What is the control of I-SceI? rtTA, P~TRE~ and P~CAG~ are not defined.

2\) The authors must discuss the unexpected result that HR is increased without a concomitant decrease in NHEJ. This is unexpected from the competition between both pathways, and typically mutants in one or the other pathway affect this balance in both directions. This result could also provide a key to understand the underlying mechanism, although it is understood that this contribution cannot address the underlying mechanism, but is focused on the observation as a tool.

3\) The limited immunoblot analysis in Figure 1---figure supplement 2 does not allow to conclude that protein level changes are not causative, as only a small selection of HR proteins is analyzed and no negative regulators are considered. Excluding a mechanism by trying to demonstrate a negative from a small selection of targets is not a productive strategy, although it is useful to know that the protein analyzed show no changes.

4\) The key issue that would farrerol make a useful tool is that it does induce genotoxic side effects, as shown for the SCR7 or RS-1. The analysis in Figure 4---figure supplement 2 tries to address this but needs to be expanded to include more markers of genotoxic stress (γH2AX foci, 53BP1 foci), karyotyping, and genomic analysis to monitor gross chromosomal rearrangements.

5\) The germline transmission data and conclusion in Figure 5 are based on small numbers (5 versus 0 events), and it is surprising to see no germline transmission in the controls. Any explanation?
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Author response

> Essential revisions:
>
> 1\) The screening platform and the dual reported system is not explained well in Figure 1 and needs substantial clarification. In A, what does SA and SD is not defined. How long is the homology for the HR assay part? What is the control of I-SceI? rtTA, P~TRE~ and P~CAG~ are not defined.

Thank the reviewers for the suggestion. SD stands for splice donor, and SA stands for splice acceptor. The length of the homologous sequence in our dual reporter is \~ 3.9 kb including the Pem1 intron and the inserted full length-tdTomato. The rtTA is the reverse tetracycline-controlled transactivator; P~TRE~ is the promoter containing the Tet-responsive element, which can be activated upon rtTA binding to the sequence only in the presence of tetracycline or doxycycline; and the P~CAG~ is the CAG promoter, which is a strong synthetic promoter frequently used to drive gene expression in mammalian systems. We have included more clarification in figure legends (Figure 1; Figure 1---figure supplements 1 and 3). In our previous work (Chen et al., 2019), we characterized HCA2-D4a, the parental cell line of CLZ3 which we used for screening in this study, with a vector encoding the hypoxanthine phosphoribosyltransferase (HPRT) gene (pHPRT--CAG32) as the control of I-SceI. In HCA2-D4a cells transfected with the vector encoding HPRT gene, we did not observe GFP^+^ or tdTomato^+^ cells (Figure 1B, Chen et al., 2019), which we used as the measure of NHEJ and HR efficiency.

> 2\) The authors must discuss the unexpected result that HR is increased without a concomitant decrease in NHEJ. This is unexpected from the competition between both pathways, and typically mutants in one or the other pathway affect this balance in both directions. This result could also provide a key to understand the underlying mechanism, although it is understood that this contribution cannot address the underlying mechanism, but is focused on the observation as a tool.

We thank the reviewers for the comments. We agree with the reviewer that HR and NHEJ are two competitive pathways when repairing DSBs. Nevertheless, upon the induction of a DSB in cells, several consequences might occur: (1) cells might choose not to repair it and enter senescence or apoptosis; (2) cells choose to repair it via canonical-NHEJ or alternative NHEJ; (3) cells choose to repair it by HR, which can be further categorized into two precise pathways, gene conversion and crossing over, and single-strand annealing (SSA) pathway. As shown in our paper, we also observed that farrerol actually suppressed SSA repair (Figure 1---figure supplement 3). Therefore, the reasons leading to the increase in HR with no concomitant decline in NHEJ might lie in that (1) the balance of three sub-HR pathways shifts from SSA to the two precise sub-HR pathways in the presence of farrerol; (2) fewer cells with the I-SceI induced DSBs enter senescence or apoptosis. As the reviewer suggested, we have included some discussion in the text.

> 3\) The limited immunoblot analysis in Figure 1---figure supplement 2 does not allow to conclude that protein level changes are not causative, as only a small selection of HR proteins is analyzed and no negative regulators are considered. Excluding a mechanism by trying to demonstrate a negative from a small selection of targets is not a productive strategy, although it is useful to know that the protein analyzed show no changes.

We thank the reviewers for the suggestion. We agree with the reviewer on this issue. We have included more HR factors such as CtIP, EXO1, XRCC2 and the negative regulator such as 53BP1 in the immunoblot analysis. Our results showed that farrerol did not stimulate HR by influencing the expression of these proteins. This data is shown in Figure 1---figure supplement 2A. In addition, we have rephrased our text to tone down the conclusion.

> 4\) The key issue that would farrerol make a useful tool is that it does induce genotoxic side effects, as shown for the SCR7 or RS-1. The analysis in Figure 4---figure supplement 2 tries to address this but needs to be expanded to include more markers of genotoxic stress (γH2AX foci, 53BP1 foci), karyotyping, and genomic analysis to monitor gross chromosomal rearrangements.

We thank the reviewers for the valuable suggestions. We have performed immunofluorescence experiments to investigate the level of more markers associated with genotoxicity, including γH2AX and 53BP1. The results showed that in consistent with the previous data obtained with the comet assay, in HCA2-hTERT fibroblasts farrerol treatment did not induce genotoxic side effects assayed by analysis of γH2AX and 53BP1 foci number (Figure 4; Figure 4---figure supplement 1). The γH2AX and 53BP1 immunofluorescence experiments were also carried out in mouse ESCs. By analyzing the fluorescence intensity of the γH2AX using the software ImageJ and the foci number of 53BP1, we observed that farrerol did not affect the genome integrity in mouse ESCs (Figure 4A-D). Moreover, we also performed karyotyping analysis to investigate the potential influence of these drugs on large-scaled chromosomal rearrangements. We found that both SCR7 and RS-1 treatment led to the increase in the percentage of cells with an abnormal karyotype while farrerol treatment had no obvious influence on the karyotype (Figure 4F). Taken together, these data strongly indicate that farrerol has no negative effect on genomic stability.

> 5\) The germline transmission data and conclusion in Figure 5 are based on small numbers (5 versus 0 events), and it is surprising to see no germline transmission in the controls. Any explanation?

We thank the reviewers for the comment. In the previous version we attempted to emphasize that farrerol treatment can not only efficiently improve knock-in efficiency in embryos *in vitro* but also generate more founder mice *in vivo* compared with control, and the generated mice can further transmit the modified gene to the offspring. In the revised version, we performed more experiments by increasing the sample size in the experimental group with the farrerol treatment (Figure 6E; Figure 6---figure supplement 1C). And the data further supported the conclusion. However, the only one targeted founder mouse in the control group was unable to produce knock-in offspring, as shown in our previous version of manuscript. We agree with the reviewers that most founder mice have the ability to transmit their knock-in genotype to their offspring. Thus, we hypothesized that one possible reason for our observation is that the homologous recombination is inefficient in control group and there exists a mosaic genotype which is caused by the occurrence of gene editing even after the 2- or 4-cell stage in individual blastomere, leading to the generation of the chimeric mouse. And the cells with genomic locus not edited might contribute to PGCs (Primordial germ cells), leading to the disability of germline transmission we observed.

[^1]: These authors contributed equally to this work.
